(S) -Bleximenib (oxalate)
(S) -Bleximenib (oxalate) is a S-Enantiomer of Bleximenib oxalate (HY-148669A) . Bleximenib (JNJ-75276617) oxalate is an orally active and selective menin-KMT2A inhibitor, with IC50 values of 0.1 nM, 0.045 nM, and ≤0.066 nM for humans, mice, and dogs, respectively. Bleximenib oxalate can inhibit the proliferation and induce apoptosis and differentiation of tumor cells. Bleximenib oxalate can be used in the research of tumors such as leukemia[1].
Product Specifications
Product Name Alternative
(S) -JNJ-75276617 (oxalate) ; (S) -Menin-MLL inhibitor 24 (oxalate)
UNSPSC
12352005
Target
Apoptosis; FLT3; Histone Methyltransferase
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics; Protein Tyrosine Kinase/RTK
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/s-bleximenib-oxalate.html
Purity
98.37
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
COCCN(C)CCC[C@H](N1CC2(C1)CN(C3=NC=NN=C3OC4=C(C=C(C=C4)F)C(N(CC)C(C)C)=O)CC2)C(C)C.O=C(O)C(O)=O
Molecular Formula
C34H52FN7O7
Molecular Weight
689.82
References & Citations
[1]DASKALAKIS N, et, al. Combination therapies. WO2022237720A1.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Browse additional items from our catalog
Recombinant Mycobacterium bovis Phosphoribosylaminoimidazole-succinocarboxamide synthase (purC)
Recombinant Mycobacterium bovis Phosphoribosylaminoimidazole-succinocarboxamide synthase (purC)